1029P Addition of dendritic cell vaccines to neoadjuvant chemotherapy in HER2 negative breast cancer patients
Amaia Urrizola(Clinica Universidad de Navarra), Laura Hato(Unknown), Belén P. Solans(Navarre Institute of Health Research), A. Vilalta(Clinica Universidad de Navarra), Susana Inogés(Universidad de Navarra), N. Rodríguez-Spiteri(Clinica Universidad de Navarra), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), B. Olartecoechea(Clinica Universidad de Navarra), Susana de la Cruz(Complejo Hospitalario de Navarra), Luis D. Mejías(Clinica Universidad de Navarra), Ascensión López Dı́az de Cerio(Clinica Universidad de Navarra)
Cited by 4
Related Papers
Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer
|British journal of surgery|2009|171
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
|Nature|2024|107
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
|British Journal of Cancer|2017|106
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
|JAMA Oncology|2024|77
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
|Nature Communications|2023|65